Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study

Table 6 Multivariable analysis of CMF-treated patients, N = 324*

		DFS		OS
		HR (95% CI)	P	HR (95% CI)	P
TIMP-1	Continuous variable	1.18 (0.87-1.59)	0.28	1.29 (0.87-1.91)	0.20
	High vs. low	1.23 (0.87-1.73)	0.25	1.64 (1.02-2.65)	0.04
Age	41-55 years vs. ≤ 40 years	0.60 (0.43-0.85)	0.004	0.53 (0.33-0.84)	0.007
Tumor size	Stage 2 (> 2 cm) vs. stage 1 (≤ 2 cm)	1.59 (1.07-2.38)	0.02	2.34 (1.31-4.20)	0.01
	Stage 3 (>5 cm or chest wall/skin involvement) vs. stage 1 (≤ 2 cm)	1.92 (1.15-3.22)		1.97 (0.92-4.20)
Grade	Unknown vs. poor	0.83 (0.55-1.25)	0.24	1.05 (0.60-1.84)	0.62
	Well/moderate vs. poor	0.68 (0.43-1.10)		0.74 (0.38-1.46)

* Analyses stratified for hormone receptor status, nodal status and RT on the axilla. The results for age, tumor size and grade are from the base model not including TIMP-1. TIMP-1 was added separately as a continuous variable and then as a dichotomized one. The coefficients for age, tumor size and grade were similar with TIMP-1 included.

ISSN: 1471-2407